Older patients left behind in progress against lung cancer, Yale study shows

Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale

Ian E. Krop was named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs for Yale Cancer Center and Smilow Cancer Hospital.

June 18, 2026

Vol.52 No.24

In Brief

Mina Sedrak and Vijaya Raj Bhatt to co-lead Alliance’s committee on cancer care for older adults

Mina Sedrak, director of the UCLA Center for Cancer and Aging and director of Cancer Control and Survivorship Research at the UCLA Health Jonsson Comprehensive Cancer Center, and Vijaya Raj Bhatt professor and medical director of the Leukemia Program at the University of Nebraska Medical Center, were selected to serve as co-chairs of the Cancer in the Older Adult Committee for The Alliance for Clinical Trials in Oncology.

June 05, 2026

Vol.52 No.22

Clinical Roundup

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

A head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive non-small cell lung cancer could help oncologists fine-tune first-line TKI selection beyond what’s been seen in clinical trials alone, according to a study conducted by a team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in options over recent decades that have created meaningful improvements in lifespan and quality of life for many patients.

May 15, 2026

Vol.52 No.19

Clinical Roundup

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Diaceutics has released research revealing a critical shift in precision medicine. Despite major advances in biomarker testing, nearly two-thirds of eligible patients with advanced non-small cell lung cancer in the U.S. are still not receiving the most appropriate treatment.

May 01, 2026

Vol.52 No.17

In Brief

Sen. Susan Collins and patient advocate Jill Feldman are recognized with AACR Distinguished Service Awards

The American Association for Cancer Research will honor leaders from government and the advocacy community with awards for distinguished service in support of cancer research at the AACR Annual Meeting 2026 to be held April 17-22 in San Diego.

April 17, 2026

Vol.52 No.15

Older patients left behind in progress against lung cancer, Yale study shows

YOU MAY BE INTERESTED IN

Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale

Mina Sedrak and Vijaya Raj Bhatt to co-lead Alliance’s committee on cancer care for older adults

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Sen. Susan Collins and patient advocate Jill Feldman are recognized with AACR Distinguished Service Awards

Renew today!

Subscriber content

Never miss an issue!

Login